Petsuksiri Janjira, Frank Steven J, Garden Adam S, Ang K Kian, Morrison William H, Chao K S Clifford, Rosenthal David I, Schwartz David L, Ahamad Anesa, Esmaeli Bita
Division of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer. 2008 Jan 1;112(1):111-8. doi: 10.1002/cncr.23143.
Squamous cell carcinoma (SCC) of the eyelid is a rare malignancy with metastatic potential. In the current study, the outcomes of patients with SCC of the eyelid were evaluated after definitive and postoperative radiation therapy.
The medical records of all patients treated with radiotherapy for SCC of the eyelid at 1 institution between 1950 and 2005 were reviewed. Patient records were analyzed for clinical characteristics, pathologic features, radiation techniques, and outcomes. Survival rates were calculated using the Kaplan-Meier method; factors affecting survival were assessed using the log-rank test.
During the study period, 39 patients with 42 eyelid SCCs were treated with radiotherapy. Thirty-two tumors were treated with primary radiotherapy and 10 were treated with postoperative radiotherapy after wide local excision. Surviving patients were followed for a median of 76 months. The 5-year disease-specific and overall survival rates for all patients were 86% and 71%, respectively. At 5 years, local, regional, and distant disease control rates for all tumors were 88%, 95%, and 97%, respectively. There were no significant differences in the 5-year local, regional, and distant control rates between tumors treated with definitive and those treated with postoperative radiotherapy. There were no grade 3 or 4 complications.
Primary radiotherapy for SCC of the eyelid provides excellent locoregional control with reasonable complication rates and should be considered an alternative to surgery in selected patients.
眼睑鳞状细胞癌（SCC）是一种具有转移潜能的罕见恶性肿瘤。在本研究中，对接受根治性放疗和术后放疗的眼睑SCC患者的治疗结果进行了评估。
回顾了1950年至2005年间在1家机构接受眼睑SCC放疗的所有患者的病历。分析患者记录的临床特征、病理特征、放疗技术和治疗结果。采用Kaplan-Meier法计算生存率；使用对数秩检验评估影响生存的因素。
在研究期间，39例患有42处眼睑SCC的患者接受了放疗。32处肿瘤接受了根治性放疗，10处肿瘤在广泛局部切除后接受了术后放疗。存活患者的中位随访时间为76个月。所有患者的5年疾病特异性生存率和总生存率分别为86%和71%。5年时，所有肿瘤的局部、区域和远处疾病控制率分别为88%、95%和97%。根治性放疗组和术后放疗组肿瘤的5年局部、区域和远处控制率无显著差异。无3级或4级并发症。
眼睑SCC的根治性放疗可提供良好的局部区域控制，并发症发生率合理，对于部分患者应考虑作为手术的替代方案。
